Compare EVTC & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTC | XNCR |
|---|---|---|
| Founded | 1988 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2013 | 2013 |
| Metric | EVTC | XNCR |
|---|---|---|
| Price | $29.98 | $26.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $35.80 | $22.33 |
| AVG Volume (30 Days) | 384.3K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | 27.17 | ★ 65.36 |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $453,869,000.00 | $125,576,000.00 |
| Revenue This Year | $12.68 | N/A |
| Revenue Next Year | $6.86 | $4.80 |
| P/E Ratio | $62.70 | ★ N/A |
| Revenue Growth | 11.48 | ★ 13.65 |
| 52 Week Low | $21.81 | $7.91 |
| 52 Week High | $35.41 | $30.61 |
| Indicator | EVTC | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 71.57 |
| Support Level | $28.87 | $11.20 |
| Resistance Level | $30.38 | N/A |
| Average True Range (ATR) | 0.93 | 1.35 |
| MACD | -0.17 | 0.22 |
| Stochastic Oscillator | 28.55 | 73.02 |
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions. Latin America Payments and Solutions segment derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.